BOSTON , Oct. 31, 2024 /PRNewswire/ -- In a remarkable development for cancer research, patients with advanced-stage cancer have benefited from SUPLEXA, a personalized treatment that trains the patient's own immune cells to fight cancer. "Cancer often gains the upper hand by suppressing the immune system.
Our approach flips the script: we isolate immune cells from this suppressive environment, we reactivate their inherent cancer-fighting abilities in a laboratory, and return them back to the patient", said Dr Frank Borriello , Founder and CEO of Boston -based Alloplex Biotherapeutics [1] . While the science behind SUPLEXA is sophisticated, the process for patients and clinicians is surprisingly straight-forward. A single 50 mL blood draw from the patient is all it takes to develop a complete course of SUPLEXA therapy.
With nothing more than standard lab equipment, the patient's white blood cells are isolated and 'trained' outside the body ( ex vivo ) using Alloplex's proprietary ENLIST immune cell training technology. About a month later, the enhanced blood cells are infused into the patient, where they not only seek out and destroy rogue cancer cells — that had, until then, evaded the immune system — but improve the overall immune health of the patient. Full results of the first-in-human trial [2] will be released at the 2024 SITC conference in November.
The Australian study showed no treatment-related serious adverse events — unsurprising, given that SUPLEXA is made f.
